# Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

> **NCT01573702** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Stereotactic Radiosurgery
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01573702
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-11
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01573702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01573702, "Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01573702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*